Lactose India Ltd (524202)
📢 Recent Corporate Announcements
Lactose India Limited has announced the re-appointment of M/s. AMS & CO LLP as Internal Auditors for FY 2026-27 following a Board meeting held on August 25, 2026. The Board also approved the appointment of Alpesh A. Lakeshri as Cost Auditor for the same financial year. These appointments represent routine annual statutory and internal compliance procedures with no direct impact on financial operations or commercial performance.
- Re-appointment of M/s. AMS & CO LLP Chartered Accountants as Internal Auditors for FY 2026-27
- Appointment of Alpesh A. Lakeshri (practicing CMA since August 2023) as Cost Auditor for FY 2026-27
- Board meeting approving appointments held on August 25, 2026, concluding at 5:00 PM
Lactose India Ltd held its Board of Directors meeting on August 25, 2026, approving standard annual governance items. Key approvals included the Directors' Report for FY 2025-26, the notice for the upcoming 35th Annual General Meeting (AGM), and remuneration proposals for MD Atul Maheshwari and Whole-Time Director Sangita Maheshwari. The Board also noted the resignation of M/s Kirit Mehta & Co. and appointed Alpesh A. Lakeshri as the Cost Auditor for FY 2026-27, alongside re-appointing M/s AMS & Co. as Internal Auditors.
- Approved notice convening the 35th Annual General Meeting via video conferencing
- Appointed Alpesh A. Lakeshri as Cost Auditor for FY 2026-27 following resignation of M/s Kirit Mehta & Co.
- Re-appointed M/s AMS & Co. Chartered Accountants as Internal Auditors for FY 2026-27
- Approved remuneration for MD Atul Maheshwari and WTD Sangita Maheshwari, subject to shareholder approvals
Lactose India held a board meeting on 25th August 2026 to approve standard pre-AGM procedural items. The board approved the Director's Report for FY 2025-26 and the draft notice convening the company's 35th Annual General Meeting via electronic mode. Additionally, the board approved the remuneration for Managing Director Atul Maheshwari and Whole Time Director Sangita Maheshwari, alongside the approval of related party transactions. The company re-appointed M/s. AMS & Co. as internal auditors and appointed Alpesh A. Lakeshri as cost auditor for FY 2026-27 following the resignation of M/s. Kirit Mehta & Co.
- Approved draft notice for the upcoming 35th Annual General Meeting to be conducted via VC/OAVM
- Approved remuneration packages for MD Atul Maheshwari and Whole Time Director Sangita Maheshwari
- Noted resignation of Cost Auditor M/s. Kirit Mehta & Co. and appointed Alpesh A. Lakeshri for FY 2026-27
- Re-appointed M/s. AMS & Co., Chartered Accountants, as internal auditors for FY 2026-27
Lactose (India) Limited has received the certified true copy of the Hon'ble NCLT Ahmedabad Bench order dated August 5, 2026, sanctioning the Scheme of Amalgamation with Vitanosh Ingredients Private Limited. The certified order copy was received by the company on August 20, 2026. The scheme will become effective upon subsequent statutory filings, after which financial and operational integration details will take effect.
- NCLT Ahmedabad Bench sanctioned the Scheme of Amalgamation vide order dated August 5, 2026
- Certified true copy of the NCLT order received by the company on August 20, 2026
- Scheme involves the merger of Vitanosh Ingredients Private Limited into Lactose (India) Limited under Sections 230-232 of the Companies Act, 2013
Lactose India Ltd has received the certified true copy of the NCLT Ahmedabad Bench order sanctioning the Scheme of Amalgamation with Vitanosh Ingredients Private Limited. The order, dated August 5, 2026, was received by the company on August 20, 2026. The merger brings the transferor entity into Lactose India (market cap of ₹125 crore, TTM revenue ₹171 crore), with formal scheme effectiveness disclosures to follow.
- Hon'ble NCLT Ahmedabad Bench approved the Scheme of Amalgamation vide order dated August 5, 2026
- Certified true copy of the NCLT order received by the company on August 20, 2026
- Scheme involves the amalgamation of Vitanosh Ingredients Private Limited into Lactose (India) Limited
- Effectiveness of the scheme and subsequent corporate filings will be intimated in due course
Lactose India reported a strong start to FY27 with Q1 revenue growing 18.7% YoY to ₹46.97 Cr. Net Profit surged 58% YoY to ₹2.37 Cr, driven by improved operational performance as expenses grew slower than revenue. A significant balance sheet event occurred as 15,00,000 warrants were forfeited due to non-payment of the remaining 75% exercise price, resulting in ₹6.525 Cr being transferred to Capital Reserves. The company also confirmed that its merger with Vitanosh Ingredients is currently awaiting final SEBI and NCLT approvals.
- Revenue from operations increased 18.7% YoY to ₹46.97 Cr from ₹39.58 Cr.
- Net Profit after tax grew 58% YoY to ₹2.37 Cr compared to ₹1.50 Cr in the previous year's quarter.
- Forfeited ₹6.525 Cr in upfront warrant payments after holders failed to pay the balance 75% by the June 5, 2026 deadline.
- Earnings Per Share (EPS) improved to ₹1.88 from ₹1.19 in the year-ago period.
- Total Comprehensive Income for the quarter stood at ₹2.37 Cr vs ₹1.50 Cr YoY.
Lactose India reported a strong Q1 FY27 with revenue growing 18.7% YoY to Rs 46.97 Cr and Net Profit increasing 58% to Rs 2.37 Cr. A significant non-operational event occurred as the company forfeited Rs 6.525 Cr (25% upfront payment) from 15 lakh unexercised warrants, transferring the amount to Capital Reserve. The warrant exercise price was Rs 174, significantly above the current market price of Rs 102, explaining the non-exercise. Additionally, the merger with Vitanosh Ingredients is progressing, having received shareholder approval and now awaiting NCLT/SEBI clearance.
- Revenue from operations increased 18.7% YoY to Rs 46.97 Cr in Q1 FY27.
- Net Profit surged 58% YoY to Rs 2.37 Cr from Rs 1.50 Cr in the previous year's quarter.
- Forfeited Rs 6.525 Cr from 15,00,000 unexercised warrants, representing ~10% of the company's net worth.
- Basic EPS improved to Rs 1.88 for the quarter, up from Rs 1.19 in Q1 FY26.
- Merger with Vitanosh Ingredients Private Limited is pending final SEBI and NCLT approvals.
Lactose India has scheduled a board meeting for August 11, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The company enters this period with a TTM revenue of ₹163 Cr and a PAT of ₹6 Cr. Investors will be monitoring if the company can maintain its 20% growth trajectory and improve operating margins, which stood at 11% in FY26 compared to 15% in FY25. The trading window for insiders has been closed since July 1, 2026.
- Board meeting scheduled for August 11, 2026, to approve Q1 FY27 results.
- Trading window closed from July 1, 2026, until 48 hours after the results declaration.
- Company reported FY26 revenue of ₹163 Cr, representing a 40.5% increase over FY25 revenue of ₹116 Cr.
- Operating profit margin (OPM) for FY26 was 11.0%, down from 15.0% in the previous fiscal year.
CRISIL Ratings has reaffirmed its 'CRISIL BBB-/Stable' rating for the bank facilities of Lactose India Ltd. Notably, the total rated bank loan facilities have been enhanced by 50%, increasing from ₹60 crore to ₹90 crore. This enhancement includes a new ₹30 crore term loan from Bank of Baroda and ₹60 crore in cash credit limits across two banks. The stable outlook reflects the agency's expectation of steady operational performance and timely debt servicing.
- Total rated bank loan facilities increased to ₹90 crore from the previous ₹60 crore.
- Long-term rating reaffirmed at 'CRISIL BBB-/Stable' with a stable outlook.
- New Term Loan of ₹30 crore sanctioned by Bank of Baroda for long-term requirements.
- Cash credit facilities maintained at ₹60 crore, split between Bank of Baroda (₹35 cr) and YES Bank (₹25 cr).
- The rating letter remains valid for use until March 31, 2027.
Financial Performance
Revenue Growth by Segment
The company operates in a single Pharmaceutical Business segment. Revenue grew 2.2% YoY from INR 113.89 Cr in FY24 to INR 116.40 Cr in FY25, driven by direct sales and increased capacity utilization.
Geographic Revenue Split
Not disclosed in available documents, though the company is targeting expansion in South Asia and Africa.
Profitability Margins
Gross margins were impacted by rising costs; Operating Profit Margin declined from 16.68% to 14.57% YoY. Net Profit Margin fell from 5.74% to 4.39% YoY due to higher interest and depreciation costs.
EBITDA Margin
EBITDA margin stood at 14.9% in FY25. Core profitability was affected by sub-scale business model pressures and increased operating expenses.
Capital Expenditure
The company is undertaking significant expansion, doubling Lactose capacity to 20,000 MTPA and increasing Lactulose capacity to 3,500-5,000 MTPA. Specific historical capex value in INR Cr is not disclosed.
Credit Rating & Borrowing
The company maintains an above-average financial risk profile with an ROCE over 12%. Current borrowings increased 118% YoY to INR 30.31 Cr in FY25 to fund working capital and expansion.
Operational Drivers
Raw Materials
Raw materials include inputs for Lactose and Lactulose manufacturing (typically whey/permeate), representing a significant but unspecified percentage of total costs.
Import Sources
Not specifically disclosed, though the company identifies the setup of the raw material supply chain as a key concern due to increased sales volume.
Key Suppliers
Not specifically named, but the company has a strategic association with the Kerry Group for marketing and direct sales.
Capacity Expansion
Current installed capacity includes 10,000 MTPA for Lactose and 2,400 MTPA for Lactulose. Expansion plans target 20,000 MTPA for Lactose and 3,500-5,000 MTPA for Lactulose.
Raw Material Costs
Raw material costs are a major concern due to supply chain complexities; the company is focusing on optimum utilization of its API plant to manage these costs.
Manufacturing Efficiency
Capacity utilization is increasing; the company is focusing on particle engineering for Lactose (flowability/compressibility) and process control for Lactulose API.
Logistics & Distribution
Distribution is handled through direct sales and global expos; costs as a specific percentage of revenue are not disclosed.
Strategic Growth
Expected Growth Rate
20%
Growth Strategy
Growth will be achieved by doubling Lactose capacity to 20,000 MTPA, expanding Lactulose to 5,000 MTPA, increasing exports to South Asia and Africa, and leveraging the Kerry Group partnership for direct sales.
Products & Services
Lactose Monohydrate (milled and sieved, spray-dried, anhydrous, inhalation grades), Lactulose API, and Pharmaceutical Tablets (20 lakh/day capacity).
Brand Portfolio
Lactose (India) Limited.
New Products/Services
New specialized grades of lactose (spray-dried, anhydrous, inhalation) and high-purity lactulose for prebiotic applications are expected to boost export revenue.
Market Expansion
Targeting the Asia-Pacific pharmaceutical industry (7.5% CAGR in India) and penetrating markets in South Asia and Africa.
Market Share & Ranking
Holds a 40% share of India's lactose market and operates Asia's only lactulose plant.
Strategic Alliances
Strategic association with the Kerry Group for marketing and direct sales to 70-80 registered customers.
External Factors
Industry Trends
The global pharma lactose market is growing at a 5.2% CAGR, reaching USD 3.21B by 2032. The industry is shifting toward specialized excipient grades and prebiotic applications for lactulose.
Competitive Landscape
Intense competition from both local and global players in the bulk drugs and excipients industry.
Competitive Moat
Moat is based on a 40% domestic market share in lactose and being the sole Asian manufacturer of lactulose, supported by WHO-cGMP compliance and Kerry Group's marketing reach.
Macro Economic Sensitivity
Sensitive to pharmaceutical sector profitability and the 7.5% CAGR of the Indian pharma industry.
Consumer Behavior
Increased demand for binders in solid oral dosage forms and rising prebiotic/liver-care therapy trends are driving demand.
Geopolitical Risks
Trade barriers in target export markets like South Asia and Africa could impact the 20% growth target.
Regulatory & Governance
Industry Regulations
Operations must adhere to WHO-cGMP, ISO 9001:2008, and EXCiPACT standards. Cost records are maintained under Section 148(1) of the Companies Act.
Taxation Policy Impact
Current tax liability for FY25 was INR 69.82 lakhs.
Legal Contingencies
No whistle-blower complaints were received. The company has no subsidiaries or joint ventures, simplifying its regulatory reporting structure.
Risk Analysis
Key Uncertainties
Large working capital requirements (GCA 160-175 days) and the need for debt-funded capex pose risks to the capital structure and liquidity.
Geographic Concentration Risk
Manufacturing is concentrated in Vadodara, Gujarat; revenue is primarily domestic (40% India market share) with growing export targets.
Third Party Dependencies
Dependency on the Kerry Group for marketing and direct sales reach.
Technology Obsolescence Risk
The company is mitigating tech risks by investing in automation and R&D for specialized particle engineering.
Credit & Counterparty Risk
Receivables quality is monitorable; Debtors Turnover Ratio slowed from 8.17 to 6.29 YoY, indicating a stretch in the credit cycle.
